Management

James Powers Chief Executive Officer
James Powers
Chairman and CEO

James C. Powers was appointed full-time CEO in February 2009. Prior to joining HemoShear, Mr. Powers spent 20 years as an executive in the pharmaceutical R&D services sector, 18 of those with global firm PRA International where he grew the company from a niche services provider to a global clinical trials management organization; revenue grew from annual sales of less than $1 million to more than $450 million and staff from a few employees to a global work force of more than 3,000 employees. Mr. Powers launched PRA’s oncology therapeutic focus, a market in which PRA continues to be a leader, and was instrumental in strategic planning and eight acquisitions. PRA International had a successful IPO in 2004. He was an advisor to the Coulter Translational Research Partnership in the Biomedical Engineering Department at the University of Virginia where he met Drs. Blackman and Wamhoff. He currently serves on the boards of Gene Solutions, LLC, and Virginia BIO and is Chairman of the Virginia Bioscience Foundation. Mr. Powers received a BS in administration and management science from Carnegie-Mellon University.

Brian Wamhoff, PhD VP R&D
Brian Wamhoff, PhD
Co-founder and Vice President of Research and Development

Dr. Wamhoff leads strategic R&D initiatives to expand the HemoShear platform for commercial growth. Prior to joining HemoShear full-time, he was an associate professor at the University of Virginia in the Department of Medicine, with a joint appointment in the Department of Biomedical Engineering where he was funded by the NIH, the pharmaceutical industry, and the American Heart Association for research in vascular disease. Dr. Wamhoff has authored more than 55 peer-reviewed manuscripts and is the recipient of multiple awards for his research, including the 2004 and 2008 American Physiological Society Cardiovascular Investigator Award and the 2008 American Heart Association Irvine H. Page Award.  Dr. Wamhoff is a successful entrepreneur, having started two medical device companies, who recently testified in Congress on the role of federal funding in biotechnology entrepreneurship. Dr. Wamhoff obtained a BS in biology with a minor in business administration from Rhodes College, where he was the 2011 Distinguished Alumnus, and received his PhD in medical physiology from the University of Missouri.

For a list of publications by Brian R. Wamhoff, PhD, go to
http://www.ncbi.nlm.nih.gov/pubmed?term=wamhoff%20b.

Brett Blackman, PhD Chief Scientific Officer
Brett Blackman, PhD
Co-founder and Chief Scientific Officer

Brett R. Blackman, PhD, is co-inventor of the HemoShear technology and co-founder of HemoShear. He is responsible for scientific development of HemoShear’s commercial relationships. Prior to HemoShear, he was a tenured associate professor in the Department of Biomedical Engineering at the University of Virginia (U.Va.). At U.Va., Dr. Blackman’s lab made fundamental advances in uncovering the importance of hemodynamics and biological transport in atherosclerosis-based diseases and has made numerous novel scientific discoveries in vascular cell biology. Dr. Blackman also served in leadership positions with U.Va.’s School of Engineering and Sciences Dean’s Research Advisory Committee, the Robert M. Berne Cardiovascular Research Center and the American Heart Association Bioengineering & Biotechnology study section. Dr. Blackman trained as a postdoctoral research fellow in the Vascular Research Division, Department of Pathology of Brigham & Women’s Hospital and Harvard Medical School. He obtained a BS in mechanical engineering from Drexel University and a PhD in bioengineering from the University of Pennsylvania. Dr. Blackman currently holds the academic position of adjunct associate professor of biomedical engineering at U.Va.

For a list of publications by Brett R. Blackman, PhD, go to
http://www.ncbi.nlm.nih.gov/pubmed?term=blackman%20br.

Vincent Aurentz Chief Business Officer
Vincent Aurentz
Chief Business Officer

Vincent E. Aurentz joined HemoShear in July 2013 as Chief Business Officer. He is responsible for commercial business development, where he is expanding HemoShear’s relationships to executive levels within our partners and leads the negotiation of major partnerships and drug R&D agreements. Mr. Aurentz has worked more than 24 years in the life sciences industry. Prior to joining HemoShear, Mr. Aurentz was executive vice president of the customer solutions business at Quintiles where he created a new business model to strategically engage their customers. Prior to Quintiles, Mr. Aurentz was executive vice president at Merck KGaA and was executive vice president, portfolio development, for Merck Serono. He was a member of the Merck Serono executive management board. He is former co-founder and managing director of True North Partners, a venture capital and advisory business focused on the healthcare industry. He currently serves as the chairman of Dovetail Integrated Systems. Mr. Aurentz obtained a BS degree in mathematics from Villanova University.

Nicole Hastings, PhD VP Operations
Nicole Hastings, PhD
Vice President of Operations

Nicole E. Hastings, PhD, oversees HemoShear’s processes, internal execution and growth. She obtained her PhD from the Department of Biomedical Engineering at the University of Virginia, where she worked with the co-founders Drs. Blackman and Wamhoff to develop HemoShear’s vascular system. Dr. Hastings is an active member of Virginia BIO, the statewide biotechnology trade organization, through which she supports local STEM initiatives. Dr. Hastings is first author on two peer-reviewed publications, is co-author on five additional high-impact publications and has presented at various international meetings. Prior to obtaining her PhD at U.Va., she obtained a BS in biomedical engineering from North Carolina State University.

For a list of publications by Nicole E. Hastings, PhD, go to
http://www.ncbi.nlm.nih.gov/pubmed?term=hastings%20ne.

Richard White, CPA VP Finance
Richard White, CPA
Vice President Finance & Controller

Richard White is a CPA and tax professional. Prior to joining HemoShear in 2012, he had been HemoShear’s public accountant since the company’s formation in 2008. Mr. White was a managing partner of the Charlottesville office of Keiter, Stephens, Hurst, Gary & Shreaves, a 140 person, regional, public accounting firm. His practice included many high-potential, early-stage companies in the central Virginia area. Mr. White’s tax expertise includes corporate structure, capitalization, financing and partnership tax law. He is a visiting executive lecturer at the University of Virginia Darden School of Business and is an advisor to the Batten incubator, Darden business plan competition and Darden entrepreneurial bootcamp. He was one of the original organizers in 1998 of the Virginia Piedmont Technology Council, now called Charlottesville Business Innovation Council (CBIC), and a founding member of Charlottesville Venture Group (CVG).

Board of Directors

James Powers Chief Executive Officer
James Powers
Chairman and CEO

James C. Powers was appointed full-time CEO in February 2009. Prior to joining HemoShear, Mr. Powers spent 20 years as an executive in the pharmaceutical R&D services sector, 18 of those with global firm PRA International where he grew the company from a niche services provider to a global clinical trials management organization; revenue grew from annual sales of less than $1 million to more than $450 million and staff from a few employees to a global work force of more than 3,000 employees. Mr. Powers launched PRA’s oncology therapeutic focus, a market in which PRA continues to be a leader, and was instrumental in strategic planning and eight acquisitions. PRA International had a successful IPO in 2004. He was an advisor to the Coulter Translational Research Partnership in the Biomedical Engineering Department at the University of Virginia where he met Drs. Blackman and Wamhoff. He currently serves on the boards of Gene Solutions, LLC, and Virginia BIO and is Chairman of the Virginia Bioscience Foundation. Mr. Powers received a BS in administration and management science from Carnegie-Mellon University.

Brett Blackman, PhD Chief Scientific Officer
Brett Blackman, PhD
Co-founder and Chief Scientific Officer

Brett R. Blackman, PhD, is co-inventor of the HemoShear technology and co-founder of HemoShear. He is responsible for scientific development of HemoShear’s commercial relationships. Prior to HemoShear, he was a tenured associate professor in the Department of Biomedical Engineering at the University of Virginia (U.Va.). At U.Va., Dr. Blackman’s lab made fundamental advances in uncovering the importance of hemodynamics and biological transport in atherosclerosis-based diseases and has made numerous novel scientific discoveries in vascular cell biology. Dr. Blackman also served in leadership positions with U.Va.’s School of Engineering and Sciences Dean’s Research Advisory Committee, the Robert M. Berne Cardiovascular Research Center and the American Heart Association Bioengineering & Biotechnology study section. Dr. Blackman trained as a postdoctoral research fellow in the Vascular Research Division, Department of Pathology of Brigham & Women’s Hospital and Harvard Medical School. He obtained a BS in mechanical engineering from Drexel University and a PhD in bioengineering from the University of Pennsylvania. Dr. Blackman currently holds the academic position of adjunct associate professor of biomedical engineering at U.Va.

For a list of publications by Brett R. Blackman, PhD, go to
http://www.ncbi.nlm.nih.gov/pubmed?term=blackman%20br.

John Brooks, III Board Member
John Brooks, III
Board Member

John L. Brooks, III, is the CEO and president of the Joslin Diabetes Center in Boston. He sits on the boards of Pathfinder Cell Therapy, Noxilizer, Ammonett Pharma, Reflectance Medical, Inc., Suffolk University and Thermalin Diabetes. He was a founding partner of Prism Ventureworks. Prism has raised more than $1.25 billion and is based in Needham, MA. Mr. Brooks was formerly a general manager at Pfizer/Valleylab in Boulder, CO, where he developed and executed a minimally invasive surgery and emerging businesses strategy. Prior to Valleylab, he led the growth of a rapidly evolving vascular access medical device business at Pfizer/Strato Medical. Mr. Brooks has co-founded three paradigm-shifting life sciences companies: Songbird Hearing, Locus Pharmaceuticals and Insulet (PODD). He is a biotechnology advisory board member for Draper Labs. In addition, Mr. Brooks is a member of M2D2, an early-stage medical technology accelerator and a board member of the Massachusetts Technology Transfer Center (MTTC) advisory boards. He holds an MS in business and a BBA cum laude from the University of Massachusetts at Amherst. He is a certified public accountant and a certified financial planner.

Frederick Brown Board Member
Frederick Brown
Board Member

Frederick (Fred) W.K. Brown is an independent life sciences business strategy consultant. He was the president of the Navigator Health Services division of Diplomat Specialty Pharmacy, the largest independent specialty pharmacy in the world, which was awarded the INC 500 prize as the fastest growing healthcare company in the U.S. in 2009 and 2010. He also served as the global head of partnering and product lifecycle management at Hoffmann-La Roche. As a top healthcare consultant, Mr. Brown served as the executive vice president of Global Services EMEA, of the Life Sciences/Healthcare Division of IBM, and he co-founded Anderson Consulting’s (now Accenture’s) Pharmaceutical and Medicinal Products Practice in the US and Europe. Mr. Brown sits on the boards of FirstSense Medical, EXT Life Sciences and VersaImage Technologies. Mr. Brown was named a Benjamin G. Brown Scholar at Tufts University where he graduated magna cum laude with degrees in biology and geology. He holds an MBA from the Harvard Business School.

Mehmood Khan, MD Board Member
Mehmood Khan, MD
Board Member

Mehmood Khan, MD, is the executive vice president and chief scientific officer of PepsiCo, Inc., where he is responsible for leading all aspects of the company’s research and development and product and equipment strategy. He provides global leadership and support to division research and development groups in the areas of enterprise research planning, R&D portfolio management, next generation technologies, nutritional standards, food safety and regulation and quality assurance. Prior to joining PepsiCo in 2007, Dr. Khan served as president of Takeda Global Research & Development Center, Inc. (TGRD). Dr. Khan has also served as consultant physician in Endocrinology and Director of the Diabetes, Endocrine and Nutrition Clinical Trials Unit in the Division of Endocrinology at the Mayo Clinic in Rochester, Minn.

Dr. Khan earned his MD from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a member of the Royal College of Physicians, London and a fellow of the American College of Endocrinology.

Jonathan Sackier, MB Board Member
Jonathan Sackier, MB
Board Member

Jonathan M. Sackier, MB, ChB, FRCS, FACS, trained as a surgeon in the United Kingdom and developed and brought to market a number of healthcare innovations. He consults to health care companies, sits on several corporate and scientific advisory boards and is a visiting professor at Oxford University’s Nuffield Department of Surgical Sciences. Prior to moving to Charlottesville, he founded and funded the Washington Institute of Surgical Endoscopy at George Washington University, a center for education, research and technological innovation. In the mid-1980s, his team discovered and patented a line of amniotic stem cells and the resultant company, Genethics, licensed the rights to a publicly traded British pharmaceutical company. Dr. Sackier also helped develop Computer Motion’s AESOP robotic device, which led to a successful IPO in 1997. He is a trustee of the First Star Foundation. Dr. Sackier received his MB, ChB from the Liverpool University Faculty of Medicine and completed his fellowship with the Royal College of Surgeons in Glasgow.

W. M. Thompson, Jr. General Counsel
W. M. Thompson, Jr.
Board Member and General Counsel

W. McIlwaine (Mac) Thompson, Jr. is of counsel to the law firm of Woods Rogers PLC and specializes in representing companies in many diverse fields including biotechnology, information technology and oil and gas exploration. Mr. Thompson is secretary of Insmed Incorporated, a publicly traded biotechnology company, and is a member of the boards of Mestena Inc., an oil- and gas-exploration company, and Foundation Energy Management, LLC, which acquires oil- and gas-producing properties. He is a member of the investment advisory board of Tall Oaks Capital, a venture capital fund based in Charlottesville, and has represented many biotechnology companies in the Charlottesville area. He is also a member of the advisory board for the University of Virginia’s Heart and Vascular Center and general counsel to, and immediate past chair of, the board of the U.Va. Curry School of Education Foundation. Mr. Thompson graduated from Yale College in 1969 and the U.Va. Law School in 1972.

Brian Wamhoff, PhD VP R&D
Brian Wamhoff, PhD
Co-founder and Vice President of Research and Development

Dr. Wamhoff leads strategic R&D initiatives to expand the HemoShear platform for commercial growth. Prior to joining HemoShear full-time, he was an associate professor at the University of Virginia in the Department of Medicine, with a joint appointment in the Department of Biomedical Engineering where he was funded by the NIH, the pharmaceutical industry, and the American Heart Association for research in vascular disease. Dr. Wamhoff has authored more than 55 peer-reviewed manuscripts and is the recipient of multiple awards for his research, including the 2004 and 2008 American Physiological Society Cardiovascular Investigator Award and the 2008 American Heart Association Irvine H. Page Award.  Dr. Wamhoff is a successful entrepreneur, having started two medical device companies, who recently testified in Congress on the role of federal funding in biotechnology entrepreneurship. Dr. Wamhoff obtained a BS in biology with a minor in business administration from Rhodes College, where he was the 2011 Distinguished Alumnus, and received his PhD in medical physiology from the University of Missouri.

For a list of publications by Brian R. Wamhoff, PhD, go to
http://www.ncbi.nlm.nih.gov/pubmed?term=wamhoff%20b.

Reginald Woods Chairman
Reginald Woods
Chairman, Executive Committee

Reginald F. Woods began his business career at General Electric marketing computers and later served as director of new aircraft development for a major airline. He then joined Butler Aviation International to manage a corporate turnaround that became the subject of three Harvard Business School case studies. He led Butler through a major restructuring without any loss to banks or bondholders, or any dilution of the original public shareholders. The Butler companies generated significant earnings expansion through organic growth and acquisitions in their respective industries. He is currently active in startup companies based on technologies originated at the University of Virginia. He is a founding director and chairman of Dynamic Literacy, LLC and is a director of Scitent, Inc. He also serves on the board of Habitat for Humanity of Greater Charlottesville, the advisory board of the University of Virginia Heart and Vascular Center, and is co-founder of the Keswick Community Foundation. He earned BS and MS degrees in engineering and an MBA from Cornell University.

Advisors

Clinical Experts

Szilard Voros, MD

SzilardVoros, MD, FACC, FSCCT, FAHA, is an expert in cardiovascular imaging and cardiovascular genomics and biomarkers, and began his career at the University of Alabama at Birmingham. He completed his cardiovascular fellowship training at the University of Virginia, where he focused on translational research in cardiovascular imaging and developed an interest in atherosclerosis and lipoprotein biology research.

In 2005, Dr. Voros joined the Piedmont Heart Institute (PHI) as medical director of Cardiovascular Magnetic Resonance Imaging and Computed Tomography. There he established a lipoprotein metabolism laboratory, utilizing novel ELISA techniques, mass-spectrometry and an active in vascular biology research practice investigating the role of atherogenic lipoproteins in the development of human atherosclerosis. At the Piedmont Heart Institute, he also served as the chief scientific officer, as well as the chief of cardiovascular prevention and wellness.

In 2012, Dr. Voros joined the faculty at Stony Brook University Medical Center in the Departments of Radiology and Medicine/Cardiology as the director of advanced cardiovascular MR and CT research as an associate professor of radiology and medicine/cardiology. In August of 2012, he founded Global Genomics Group, LLC (“G3”) and serves as the chief executive officer for G3, as well as chief clinical strategy officer for Health Diagnostic Laboratory, Inc., both based in Richmond, VA. Dr. Voros maintains a voluntary faculty position at Stony Brook University. Dr. Voros completed his MD degree in his home country of Hungary in 1996. He moved to the United States in 1996 and completed his internship and residency in internal medicine at the University of Alabama at Birmingham between 1997 and 2000, where he also served as a clinical instructor in medicine and chief medical resident.

Partnerships and R&D Initiatives

Robert Ruffolo, Jr., PhD

Robert Ruffolo, Jr., PhD, DSc, DEng, is the recently-retired president of research and development for Wyeth Pharmaceuticals, and corporate senior vice president of Wyeth. In that role, he managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion. He joined Wyeth in 2000 as executive vice president responsible for pharmaceutical research and development, where he led the transformation of the Wyeth R&D pipeline and added many promising new drug candidates. Prior to joining Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), where he was senior vice president and director of biological sciences, worldwide. Before joining SmithKline Beecham, Dr. Ruffolo spent six years at Lilly Research Laboratories, where he was chairman of the Cardiovascular Research Committee.

During his career in the pharmaceutical industry, Dr. Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including Carvedilol (Coreg/Kredex/Dilatrend) for the treatment of congestive heart failure, acute myocardial infarction and hypertension; Ropinerole (Requip) for Parkinson’s disease; Dobutamine (Dobutrex) for congestive heart failure; and Eprosartan (Teveten) for hypertension. Dr. Ruffolo has won numerous prestigious awards, including the 2008 Scrip Lifetime Achievement Award and the 2008 Discoverer’s Award for the discovery and development of Carvedilol (Coreg). Dr. Ruffolo received his PhD in pharmacology and his BS in pharmacy summa cum laude with distinction, both from The Ohio State University. He is the adjunct professor of pharmacology at The Ohio State University and adjunct professor of physiology and pharmacology at the West Virginia University School of Medicine.

Since his retirement, Dr. Ruffolo has been involved in various philanthropic endeavors. He and his wife underwrote the complete renovation of the Robert & Stephany Ruffolo Lecture Hall in the College of Pharmacy at his alma mater, The Ohio State University, and they have established endowed scholarships and/or fellowships at The Ohio State University, West Virginia University and the University of Florida. He also sits on the boards of directors for several biotechnology companies as well as non-profit charitable organizations.

Mark Powell, PhD

Mark L. Powell, PhD, retired from the pharmaceutical industry in 2011 after 32 years. He is currently a global consultant to the same industry. Prior to retirement, he was the senior vice president and worldwide head of non-clinical development (NCD) at Bristol-Myers Squibb. He was responsible for the worldwide planning and directing of all NCD activities for all BMS compounds (small molecules and biologics) in global development, as well as supporting globally manufactured products as necessary. Non-clinical development consisted of drug safety evaluation, early and late phase chemical development, chemical development operations, clinical supply operations, analytical and bioanalytical development, environmental health and safety, drug product science and technology and business operations and cmc writing. In addition to his functional responsibilities, Dr. Powell was the head of diabetes exploratory development at BMS from 2000-2005. In that capacity, he was responsible for the pharmaceutical, preclinical and clinical exploratory development and progression of all diabetes compounds transitioning out of discovery and into Phase III clinical development.

Dr. Powell has authored and co-authored more than 125 scientific articles and presentations which have been made at the local, national and international levels, as well as given numerous invited talks. He participated in, and moderated, many scientific discussion panels at both national and international meetings and has chaired an international scientific conference. In addition to his advisory role with HemoShear, he is currently a senior scientific consultant to Yangtze River Pharmaceuticals in China and WuXiApptech in China. Dr. Powell obtained his PhD from the University of Washington in 1980.

Safety

Gerald Fisher, PhD

Gerald Fisher, PhD, began his career at the University of California, Davis in 1975 and progressed through several research positions focused on the area of inhalation toxicology. He joined Battelle in Columbus, OH in 1980 and during his nine years there advanced to the position of vice president of the Health and Environmental Effects Center. From 1989 to 1992, he served as vice president of drug safety and metabolism for Sandoz Research Institute in East Hanover, NJ. He joined Wyeth Pharmaceuticals in 1992 as vice president, drug safety and metabolism and was promoted to senior vice president in 1998. In January 2005, he assumed the role of chief preclinical scientist for Wyeth as senior vice president, Office of the President.

Dr. Fisher has a PhD in chemical ecology from the University of California, Davis, an MA from the University of California, Santa Barbara and a BA from Northeastern University. He has published more than 160 scientific papers, and he is the former editor of Drug and Chemical Toxicology and a member of the editorial boards of several pharmacology and toxicology journals.

Business Strategy & Licensing

John LaMattina, PhD

John L. LaMattina, PhD, is the former senior vice president, Pfizer Inc. and president of Pfizer global research and development. In this role, Dr. LaMattina supervised the drug discovery and development efforts of more than 12,000 colleagues in the United States, Europe and Asia. During his tenure, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. He retired from this position in December 2007. He is currently a senior partner at PureTech Ventures and also serves on the board of directors of Human Genome Sciences, the board of directors of Ligand Pharmaceuticals, the scientific advisory board of Trevena and the board of trustees of Boston College, where he chairs the Academic Affairs Committee.

Dr. LaMattina attended the University of New Hampshire working with Professor Robert E. Lyle and received a PhD from UNH in organic chemistry. He graduated cum laude from Boston College with a BS in chemistry. He is the author of numerous scientific publications and holds a number of U.S. patents. Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.

Mervyn Turner, PhD

Mervyn Turner, PhD, has more than 25 years of experience in pharmaceutical research and development, global licensing and strategy development. Dr. Turner retired recently from his position as Merck’s first chief strategy officer, where he drove strategy planning and resource allocation. As head of worldwide licensing & external research, he led the transformation of Merck & Co., Inc. to embrace external sources of innovation and collaboration. He was personally involved in more than 200 strategic transactions, including mergers and acquisitions. Prior to that, he was the site head for both Merck & Co. Inc.’s R&D facility in Rahway, NJ, and Merck Frosst, Canada.

Dr. Turner received a BS and PhD in chemistry from the University of Sheffield. He completed postdoctoral research on the biochemistry of histocompatibility at Harvard University.

Jed Beitler, MBA

JedBeitler, MBA, is the worldwide chairman and chief executive officer of Sudler & Hennessey, a global healthcare communications agency. He has been in the healthcare marketing, education and communications field for more than 35 years. Mr. Beitler started his career in that industry in market research and, over the years, has been involved in many aspects of the business including training & development, public relations, consumer and professional promotion, customer relationship marketing, digital and interactive marketing and professional, patient and community education.

Mr. Beitler was a non-executive director for the World Economic Forum’s Global Health Initiative. Among his other business-related activities, he has worked on the treatment advisory board for NMAC, the National Minority AIDS Council; the Global Medical Forum; and the World Economic Forum’s Global Health Initiative project on Building Healthcare Infrastructures and Capabilities in Sub-Saharan Africa for Aids, TB and Malaria. He was a contributing author for Medicine Avenue 2: The Story of Medical Advertising in America 1990-2008 and has been a guest lecturer at Harvard Medical School and Tama University in Japan.

Mr. Beitler received his BS in biology at Upsala College, completed his course work for an MBA in pharmaceutical marketing at Fairleigh Dickinson and did postgraduate studies at Wharton School of Business and at Babson College.

Wendy Yarno, MBA

Wendy Yarno, MBA, has more than 26 years of experience in the pharmaceutical industry with Johnson & Johnson and Merck & Co., Inc. Prior to joining HemoShear, she was the chief marketing officer at Merck & Co., Inc., where she was responsible for building global marketing and medical support capabilities. She also served as general manager of the cardiovascular/metabolic U.S. business unit, executive vice president of worldwide human health marketing, vice president of worldwide cholesterol reducers human health marketing, and vice president of the hypertension and heart failure therapeutic business group. Her Merck responsibilities included P&L and global marketing, sales, and business strategies across more than 20 therapeutic areas.

At Johnson & Johnson’s Ortho-McNeil Pharmaceutical division, Ms. Yarno was vice president for the women’s health care franchise, which was J&J’s highest-producing product line. During her tenure the group launched the first direct-to-consumer TV campaign for an oral contraceptive. She is currently on the board of directors of St. Jude Medical, a medical device company headquartered in Minneapolis, MN; ADial Pharmaceuticals; and PluroGen Therapeutics, both in Charlottesville, VA. Ms. Yarno is also on the board of advisors of OpenQ, Audax Health Solutions and the UVa Heart and Vascular Center. Ms. Yarno has an MBA from Temple University in Philadelphia, PA, and a BS in marketing from Portland State University in Portland, OR.

Operational Strategy

Michael King, PhD

Michael L. King, PhD, has a broad record of achievement in vaccine and pharmaceutical process technology development and manufacturing operations. He is currently lecturing on “The Business of New Product Development” as part of the engineering business minor at the University of Virginia (U.Va.) and previously served as the Brenton S. Halsey Distinguished Visiting Professor at U.Va. Prior to accepting his appointments at U.Va., Dr. King was the senior vice president and advisor to the chairman, president and CEO of Merck & Co. after serving as senior vice president of science and technology for the Merck manufacturing division and as a member on the board of directors for the Sanofi-Pasteur MSD Joint Venture. Dr. King is active in the American Institute of Chemical Engineers and the American Chemical Society. He has served on academic advisory boards at U.Va., the University of Delaware and the University of California-Berkeley. Dr. King also served on the board of directors of the National Action Council for Minorities (NACME), culminating with his election as chairman in 2004-2006. He is currently serving on the Board of Directors for ADial Pharmaceuticals and on the Advisory Board for the Delaware INBRE (biomedical research network).

Dr. King received his PhD in chemical engineering from the University of Delaware, his MS in chemical engineering from U.Va., and his BS in chemical engineering from Virginia Tech.

David Patteson

David B. Patteson is the president and CEO of Advion BioSciences, Inc., and a member of the company’s board of directors. Advion is the largest privately held bioanalytical research company in the world, and a supplier of microfluidic chemistry systems for clinical diagnostics and drug discovery research. Prior to Advion, Mr. Patteson served as president and CEO of Biotage, a major life science company traded on the Stockholm Stock Exchange, and was a member of Biotage’s executive committee. Under Mr. Patteson’s tenure, Advion made four acquisitions and established itself as the largest global supplier of systems and consumables for pharmaceutical chemistry discovery research. Prior to Biotage, he served as corporate vice president for Siebe, PLC’s $250 million measurement and controls business where he managed 1,200 employees with global R&D and production operations. Mr. Patteson holds degrees from both the University of Richmond and Virginia Tech, and completed a multi-national course in International Management conducted through the Institute for Management Development (IMD) in Lausanne, Switzerland. He is a member of the board of directors of the University of Virginia Foundation, where he has served as the chairman of the finance and audit committee and chairman of the marketing committee. He also serves on an advisory board at the University of Richmond and as a member of the board of directors for two privately held biotechnology companies.